Open AccessParkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Author(s) -
Kevin McFarthing,
Sue Buff,
Gary Rafaloff,
Thea Dominey,
Richard Wyse,
Simon Stott
Publication year - 2020
Publication title -
journal of parkinson's disease/journal of parkinson's disease (online)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.747
H-Index - 45
eISSN - 1877-718X
pISSN - 1877-7171
DOI - 10.3233/jpd-202128
Subject(s) - clinical trial , medicine , disease , drug trial , drug , intensive care medicine , clinical research , pharmacology
The majority of current pharmacological treatments for Parkinson's disease (PD) were approved for clinical use in the second half of the last century and they only provide symptomatic relief. Derivatives of these therapies continue to be explored in clinical trials, together with potentially disease modifying therapies that can slow, stop or reverse the condition.